Back to Search
Start Over
Treatment of leishmaniasis with chemotherapy and vaccine: a mathematical model.
- Source :
- Journal of Biological Dynamics; Dec2023, Vol. 17 Issue 1, p1-30, 30p
- Publication Year :
- 2023
-
Abstract
- Leishmaniasis, an infectious disease, manifests itself mostly in two forms, cutaneous leishmaniasis (CL) and, a more severe and potentially deadly form, visceral leishmaniasis (VL). The current control strategy for leishmaniasis relies on chemotherapy drugs such as sodium antimony gluconate (SAG) and meglumine antimoniate (MA). However, all these chemotherapy compounds have poor efficacy, and they are associated with toxicity and other adverse effects, as well as drug resistance. While research in vaccine development for leishmaniasis is continuously progressing, no vaccine is currently available. However, some experimental vaccines such as LEISH-F1+MPL-SE (V) have demonstrated some efficacy when used as drugs for CL patients. In this paper we use a mathematical model to address the following question: To what extent vaccine shots can enhance the efficacy of standard chemotherapy treatment of leishmaniasis? Starting with standard MA treatment of leishmaniasis and combining it with three injections of V , we find, by Day 84, that efficacy increased from 29% to 65–91% depending on the amount of the vaccine. With two or just one injection of V , efficacy is still very high, but there is a definite resurgence of the disease by end-time. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17513758
- Volume :
- 17
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Journal of Biological Dynamics
- Publication Type :
- Academic Journal
- Accession number :
- 175233746
- Full Text :
- https://doi.org/10.1080/17513758.2023.2257746